Floatz logo

18 assets in Essential Thrombocythemia

Therapeutic assets addressing Essential Thrombocythemia, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Fludarabine
Essential Thrombocythemia
Thomas Jefferson UniversityP2BB (64)
Tacrolimus
Essential Thrombocythemia
Thomas Jefferson UniversityP2BB (64)
Cyclophosphamide
Essential Thrombocythemia
Thomas Jefferson UniversityP2B (62)
Ruxolitinib
Essential Thrombocythemia
University of WashingtonP2B (62)
Carboplatin
Essential Thrombocythemia
National Cancer Institute (NCI)P2B (60)
Decitabine
Essential Thrombocythemia
University of WashingtonP2B (60)
Nogitecan
Essential Thrombocythemia
National Cancer Institute (NCI)P2B (60)
Veliparib
Essential Thrombocythemia
National Cancer Institute (NCI)P2B (60)
Azacitidine
Essential Thrombocythemia
M.D. Anderson Cancer CenterP1/2B (57)
Fedratinib
Essential Thrombocythemia
University of WashingtonP2CCC (53)
Melphalan
Essential Thrombocythemia
Thomas Jefferson UniversityP2CCC (53)
Pevonedistat
Essential Thrombocythemia
M.D. Anderson Cancer CenterP1/2CCC (48)
Venetoclax
Essential Thrombocythemia
M.D. Anderson Cancer CenterP1/2CCC (48)
Pacritinib
Essential Thrombocythemia
University of WashingtonP2CC (46)
Glb-001
Essential Thrombocythemia
Hangzhou GluBio Pharmaceutical Co., Ltd.P1CC (43)